Patients with non-GCB DLBCL and PD-L1 expression are approximately 17% less likely to survive after 5 years than those without PD-L1 expression.

News

Treatment with venetoclax and rituximab significantly improved PFS among patients with relapsed or refractory CLL when compared with rituximab and chemotherapy.
Individuals aged 75 or older with blood cancer are often underrepresented in clinical trials, according to a study conducted by researchers at the FDA.
Patients with advanced leukemia who require blood transfusions have reduced access to high-quality end-of-life care compared with those who do not require transfusions.
A recent study found a BTK inhibitor to be highly effective and safe among previously untreated patients with Waldenström Macroglobulinemia.

Research in Review

A combination of 3 pathway inhibitors is well tolerated with activity observed in heavily pre-treated and high-risk B-cell malignancies, according to research that will be presented at the ASCO Annual Meeting (June 2-6, 2017; Chicago, IL).

-----

Related Content

Read More

A combined chemotherapy approach may eliminate the toxic effects of radiation therapy in children and young adults with Hodgkin lymphoma, according to early results of a study that will be presented at the 2017 ASCO Annual Meeting (June 2-6, 2017; Chicago, IL).

-----

Related Content

Read More

A new treatment for a rare B-cell malignancy provided an objective response rate of 41% in a clinical trial, published in Blood (published online May 10, 2017; doi:10.1182/blood-2016-12-758383).

-----

Related Content

Read More

Certain mutations in relapsed chronic lymphocytic leukemia (CLL) after targeted therapy have the potential to be used as a biomarker for relapse, according to research published in the Journal of Clinical Oncology (May 2017;35[13]:1437-1443).

-----

Related Content

Read More

Subscribe to Leukemia & Lymphoma